Hospital Services – Coverage of Gene Therapies for Sickle Cell Disease LAC 50:V.120
Amends the provisions governing inpatient hospital services, to allow reimbursement for gene therapies for sickle cell disease outside the per diem rate and paid based on the actual acquisition cost in order to take advantage of a federal rebate.